Randomized Phase II Trial of Adjuvant Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy [carboplatin + docetaxel] Alone in Patients With Resected Non-Small Cell Lung Cancer.

Trial Profile

Randomized Phase II Trial of Adjuvant Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy [carboplatin + docetaxel] Alone in Patients With Resected Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Carboplatin; Docetaxel
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Apr 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 12 Jun 2012 Planned end date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov.
    • 05 Jun 2012 Primary analysis presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top